BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Daiichi Sankyo, Inc. 

U.S. Corporate Headquarters
Two Hilton Court
Parsippany  New Jersey  07054  U.S.A.
Phone: 973-944-2600 Fax: 973-359-2645


SEARCH JOBS



About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.

The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world.

A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders.


This div will be replaced



 Key Statistics


Email:
Ownership: Public

Web Site: Daiichi Sankyo, Inc.
Employees: 3,000 in the U.S.
Symbol: DSNKY
 



Industry
Pharmaceutical


Collaborations

Eli Lilly 

ArQule, Inc. 

U3 Pharma 





 Company News
Daiichi Sankyo Cuts-and-Pastes for 5-Year Plan: Sister Companies Daiichi Sankyo, Inc. (DSNKY) and Asubio Pharma Co., Ltd. Merge 4/1/2015 6:53:23 AM
Charleston Laboratories, Inc. And Daiichi Sankyo (4568.t) Announce Completion Of A Pharmacokinetics Study On CL-108 3/12/2015 7:25:05 AM
Daiichi Sankyo (4568.t) Release: SAVAYSA (edoxaban) Now Available In U.S. Pharmacies 2/9/2015 9:04:11 AM
Growth Concerns Loom for Daiichi Sankyo (4568.t) on Drug Warning 2/9/2015 6:24:26 AM
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015 7:25:15 AM
Daiichi Sankyo, Inc. (4568.t) Announces Civil Settlement 1/9/2015 8:21:17 AM
U.S. FDA Approves Daiichi Sankyo, Inc. (4568.t)'s Once-Daily SAVAYSA™ (Edoxaban) Tablets For Reduction Of Stroke Risk In Non-Valvular Atrial Fibrillation And For The Treatment Of Venous Thromboembolism 1/9/2015 6:06:44 AM
FDA Green Lights Daiichi Sankyo (DSNKY)'s New Anti-Clotting Drug 1/9/2015 6:05:37 AM
Daiichi Sankyo, Inc. (4568.t) Launches New Formulation Of LIXIANA 60 mg Tablets (edoxaban) In Japan 12/8/2014 8:13:38 AM
Ambit Biosciences And Daiichi Sankyo, Inc. (4568.t) Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society of Hematology 12/5/2014 1:18:12 PM
12345678910...